8-K: Collegium Pharmaceutical Announces Strong 2025 Financial Guidance and Business Update

Collegium Pharmaceutical projects significant revenue and EBITDA growth for 2025, driven by the expansion of Jornay PM and continued performance of their pain portfolio.

Summary

• Collegium Pharmaceutical has released its full-year financial guidance for 2025, projecting strong growth.
• The company expects net product revenues to be between $735 million and $750 million.
• Jornay PM net revenue is anticipated to exceed $135 million in 2025.
• Adjusted EBITDA is projected to be in the range of $435 million to $450 million.
• Adjusted operating expenses are expected to be between $220 million and $230 million.
• The company completed the integration of Ironshore Therapeutics Inc. and saw accelerated growth in Jornay PM prescriptions during the 2024 back-to-school season.
• Collegium repurchased $60 million in shares in 2024 as part of a $150 million share repurchase program.

Sentiment

Score: 8

Explanation: The document conveys a positive outlook with strong financial guidance and strategic growth plans, although it acknowledges risks and uncertainties. The focus on Jornay PM and the completion of the Ironshore integration are positive signals.

Positives

• The company is projecting strong revenue and EBITDA growth for 2025.
• Jornay PM is expected to be a significant growth driver.
• The integration of Ironshore Therapeutics has been completed.
• The company has a strong track record of share repurchases.
• Collegium has a diversified portfolio of pain management medications and a growing presence in neuropsychiatry.

Negatives

• The company's forward-looking statements are subject to numerous risks and uncertainties.
• The company's non-GAAP financial measures have limitations and should not be considered a substitute for GAAP measures.
• The company's adjusted EBITDA excludes stock-based compensation, which is a significant recurring expense.

Risks

• The company faces risks related to unknown liabilities and the financial performance of its products.
• There are risks associated with commercializing and growing sales of their products.
• The company's ability to integrate Ironshore and manage relationships with licensors is a risk.
• Competition from other products and the ability to maintain regulatory approvals are also risks.
• The company's ability to obtain reimbursement and third-party payor contracts is a risk.
• The company's ability to secure adequate supplies of active pharmaceutical ingredients is a risk.
• The company's customer concentration is a risk.
• The company's estimates regarding expenses, revenue, capital requirements and need for additional financing are risks.

Future Outlook

Collegium expects significant topand bottom-line growth in 2025, driven by Jornay PM and continued performance from their pain portfolio, with targeted investments in Jornay PM expected to accelerate growth in the near-term and create significant momentum in 2026 and beyond.

Management Comments

• Vikram Karnani, President and Chief Executive Officer of Collegium, stated that in 2024, they executed on their priorities of maximizing the pain portfolio and strategically deploying capital, delivering record financial results and closing the acquisition of Ironshore.
• Vikram Karnani also stated that looking ahead to 2025 and beyond, Collegium will embark upon a new phase of growth with Jornay PM as the lead growth driver.
• Colleen Tupper, Chief Financial Officer of Collegium, stated that their 2025 financial guidance reflects expected significant topand bottom-line growth driven by the addition of Jornay PM and continued performance from their pain portfolio.
• Colleen Tupper also stated that they plan to make targeted investments in Jornay PM throughout 2025, which they expect will accelerate growth in the near-term, while creating significant momentum in 2026 and beyond.

Industry Context

This announcement reflects a strategic shift for Collegium, expanding into the neuropsychiatry market with Jornay PM while continuing to leverage their established pain management portfolio. This move aligns with the broader trend of pharmaceutical companies diversifying their product offerings to capture new growth opportunities.

Comparison to Industry Standards

• Collegium's projected revenue growth of 18% is strong compared to the average growth rate of the pharmaceutical industry, which is typically in the single-digit range.
• The company's focus on Jornay PM, a differentiated ADHD treatment, positions them well against competitors in the stimulant market, such as those offering traditional methylphenidate products.
• The projected adjusted EBITDA margin of approximately 60% is competitive with other specialty pharmaceutical companies.
• The company's strategic acquisitions, such as Ironshore, are similar to moves made by other companies to expand their product portfolios and market reach.
• The share repurchase program is a common strategy used by companies to return value to shareholders, similar to programs implemented by other companies in the sector.

Management Changes

Stakeholder Impact

• Shareholders are expected to benefit from the projected revenue and EBITDA growth, as well as the share repurchase program.
• Employees may benefit from the company's growth and expansion.
• Patients may benefit from the availability of new and improved treatment options.
• Customers may benefit from the company's commitment to improving the lives of people living with serious medical conditions.
• Suppliers and creditors may benefit from the company's financial stability and growth.

Next Steps

• Collegium will focus on commercial expansion of Jornay PM.
• The company will continue to strategically deploy capital.
• Collegium will maximize and enhance the durability of its pain portfolio.
• The company will make targeted investments in Jornay PM throughout 2025.

Key Dates

Keywords

Jornay PM, ADHD, Pain Management, Pharmaceutical, Revenue, EBITDA, Financial Guidance, Ironshore, Share Repurchase, Biopharmaceutical